Silexion Therapeutics Executes Investor Outreach Push Amid Phase 2/3 Trial
Event summary
- Silexion Therapeutics to present at two oncology-focused conferences in Boston on September 9–10, 2026
- CEO and CFO to hold one-on-one investor meetings at H.C. Wainwright Conference in New York on September 14–16, 2026
- Company advancing SIL204, a pan-KRAS RNA interference therapy, through Phase 2/3 trials for locally advanced pancreatic cancer
- Silexion highlights ongoing financial challenges, including substantial doubt about ability to continue as a going concern
The big picture
Silexion's aggressive investor engagement comes as it navigates critical Phase 2/3 trials for its lead asset, SIL204. The company's focus on KRAS-driven cancers positions it in a competitive oncology space where RNAi therapies face both scientific and financial hurdles. With substantial doubt about its ability to continue as a going concern, Silexion's ability to attract investors or partners will be key to sustaining its clinical pipeline.
What we're watching
- Trial Momentum
- Whether SIL204's Phase 2/3 results will validate the pan-KRAS approach in pancreatic cancer...
- Financial Stability
- How Silexion will address going concern risks amid clinical development costs...
- Investor Sentiment
- The pace at which Silexion can secure partnerships or additional funding...
Related topics